Biolyst › CGEMCullinan Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) on November 15, 2026. There are 8 upcoming events on record.
Cash runway is approximately 21.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Upcoming catalysts
Date Event Type Phase
November 15, 2026
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) Trial Milestone
Phase 1
December 10, 2026 est.
Next quarterly earnings (projected) Earnings
—
December 15, 2026
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus Trial Milestone
Phase 1
January 15, 2027
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Trial Milestone
Phase 1
September 30, 2027
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients Trial Milestone
Phase 1
December 30, 2027
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis Trial Milestone
Phase 1
March 15, 2028
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease Trial Milestone
Phase 1
January 15, 2029
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Trial Milestone
Phase 1/Phase 2
Track CGEM alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CGEM in the tracker
Recent history
Date Event Type Phase
October 2, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
September 24, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
September 15, 2026
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma Trial Milestone
Phase 1
September 14, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
August 13, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
August 6, 2026
Quarterly results filed (8-K) Earnings
—
June 16, 2026
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Trial Milestone
Phase 1
June 10, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
June 8, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
May 18, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
May 7, 2026
Quarterly results filed (8-K) Earnings
—
March 15, 2026
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors Trial Milestone
Phase 1
March 10, 2026
Quarterly results filed (8-K) Earnings
—
January 8, 2026
Quarterly results filed (8-K) Earnings
—
December 8, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
November 6, 2025
Quarterly results filed (8-K) Earnings
—
November 3, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
October 13, 2025
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer Trial Milestone
Phase 1/Phase 2
September 4, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
August 7, 2025
Quarterly results filed (8-K) Earnings
—
June 4, 2025
8-K filed: Material agreement, Reg FD disclosure Corporate
—
May 8, 2025
Quarterly results filed (8-K) Earnings
—
June 23, 2020
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) Trial Milestone
Phase 1/Phase 2
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.